Tejas Savant
Stock Analyst at Morgan Stanley
(2.36)
# 2,621
Out of 5,135 analysts
250
Total ratings
43.26%
Success rate
-1.07%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Underweight | $40 → $48 | $36.62 | +31.09% | 15 | Dec 2, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $513.56 | +30.46% | 16 | Dec 2, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $80 → $85 | $56.16 | +51.35% | 6 | Dec 2, 2025 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $24 | $16.23 | +47.87% | 3 | Dec 2, 2025 | |
| PSNL Personalis | Maintains: Equal-Weight | $9 → $11 | $9.00 | +22.22% | 14 | Dec 2, 2025 | |
| NTRA Natera | Maintains: Overweight | $220 → $265 | $215.53 | +22.95% | 15 | Dec 2, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $250 → $265 | $171.06 | +54.92% | 12 | Dec 2, 2025 | |
| GRAL GRAIL | Maintains: Equal-Weight | $85 → $110 | $102.28 | +7.55% | 3 | Dec 2, 2025 | |
| TXG 10x Genomics | Downgrades: Equal-Weight | $17 → $20 | $19.57 | +2.20% | 16 | Dec 2, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $69 → $76 | $75.20 | +1.06% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $16 | $15.87 | +0.82% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $120.09 | -12.57% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $9.27 | +29.45% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $10.26 | -22.03% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $7 | $4.20 | +66.67% | 9 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $8.56 | -18.22% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $2.98 | +68.07% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $4.37 | +380.55% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.63 | +22.70% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $8.95 | +346.93% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.68 | +123.88% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.83 | +107.04% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $4.17 | -34.05% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.02 | +395.05% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $107.42 | -32.04% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $158.00 | +58.23% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $12.57 | +695.54% | 5 | May 12, 2022 |
Veracyte
Dec 2, 2025
Maintains: Underweight
Price Target: $40 → $48
Current: $36.62
Upside: +31.09%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $513.56
Upside: +30.46%
Tempus AI
Dec 2, 2025
Maintains: Overweight
Price Target: $80 → $85
Current: $56.16
Upside: +51.35%
Stevanato Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $24
Current: $16.23
Upside: +47.87%
Personalis
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $11
Current: $9.00
Upside: +22.22%
Natera
Dec 2, 2025
Maintains: Overweight
Price Target: $220 → $265
Current: $215.53
Upside: +22.95%
IQVIA Holdings
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $171.06
Upside: +54.92%
GRAIL
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $85 → $110
Current: $102.28
Upside: +7.55%
10x Genomics
Dec 2, 2025
Downgrades: Equal-Weight
Price Target: $17 → $20
Current: $19.57
Upside: +2.20%
Hologic
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $69 → $76
Current: $75.20
Upside: +1.06%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $15.87
Upside: +0.82%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $120.09
Upside: -12.57%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $9.27
Upside: +29.45%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $10.26
Upside: -22.03%
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $4.20
Upside: +66.67%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $8.56
Upside: -18.22%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.98
Upside: +68.07%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $4.37
Upside: +380.55%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.63
Upside: +22.70%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $8.95
Upside: +346.93%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.68
Upside: +123.88%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.83
Upside: +107.04%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $4.17
Upside: -34.05%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.02
Upside: +395.05%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $107.42
Upside: -32.04%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $158.00
Upside: +58.23%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $12.57
Upside: +695.54%